|
1.
|
Brenner H, Rothenbacher D and Arndt V:
Epidemiology of stomach cancer. Methods Mol Biol. 472:467–477.
2009. View Article : Google Scholar
|
|
2.
|
Du C, Zhou Y, Cai H, Zhao G, Fu H and Shi
YQ: Poor prognostic factors in patients with stage I gastric cancer
according to the seventh edition TNM classification: a comparative
analysis of three subgroups. J Surg Oncol. 105:323–328. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Lazar D, Taban S, Sporea I, et al: Gastric
cancer: correlation between clinicopathological factors and
survival of patients (III). Rom J Morphol Embryol. 50:369–379.
2009.PubMed/NCBI
|
|
4.
|
Lazar D, Taban S, Sporea I, et al: Gastric
cancer: correlation between clinicopathological factors and
survival of patients. II. Rom J Morphol Embryol. 50:185–194.
2009.PubMed/NCBI
|
|
5.
|
Tsukita S and Furuse M: Claudin-based
barrier in simple and stratified cellular sheets. Curr Opin Cell
Biol. 14:531–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Tobioka H, Isomura H, Kokai Y, Tokunaga Y,
Yamaguchi J and Sawada N: Occludin expression decreases with the
progression of human endometrial carcinoma. Hum Pathol. 35:159–164.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Pope JL, Bhat AA, Sharma A, et al:
Claudin-1 regulates intestinal epithelial homeostasis through the
modulation of Notch-signalling. Gut. Jun 13–2013.Epub ahead of
print.
|
|
8.
|
Noda S, Tanabe S and Suzuki T: Naringenin
enhances intestinal barrier function through the expression and
cytoskeletal association of tight junction proteins in Caco-2
cells. Mol Nutr Food Res. 57:2019–2028. 2013. View Article : Google Scholar
|
|
9.
|
Iraha A, Chinen H, Hokama A, et al:
Fucoidan enhances intestinal barrier function by upregulating the
expression of claudin-1. World J Gastroenterol. 19:5500–5507. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Myal Y, Leygue E and Blanchard AA: Claudin
1 in breast tumorigenesis: revelation of a possible novel ‘claudin
high’ subset of breast cancers. J Biomed Biotechnol.
2010:9568972010.PubMed/NCBI
|
|
11.
|
Blanchard AA, Ma X, Dueck KJ, et al:
Claudin 1 expression in basal-like breast cancer is related to
patient age. BMC Cancer. 13:2682013. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Chang TL, Ito K, Ko TK, et al: Claudin-1
has tumor suppressive activity and is a direct target of RUNX3 in
gastric epithelial cells. Gastroenterology. 138:255–265. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Qin W, Ren Q, Liu T, Huang Y and Wang J:
MicroRNA-155 is a novel suppressor of ovarian cancer-initiating
cells that targets CLDN1. FEBS Lett. 587:1434–1439. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Chao YC, Pan SH, Yang SC, et al: Claudin-1
is a metastasis suppressor and correlates with clinical outcome in
lung adenocarcinoma. Am J Respir Crit Care Med. 179:123–133. 2009.
View Article : Google Scholar
|
|
15.
|
Dhawan P, Singh AB, Deane NG, et al:
Claudin-1 regulates cellular transformation and metastatic behavior
in colon cancer. J Clin Invest. 115:1765–1776. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Kinugasa T, Akagi Y, Ochi T, et al:
Increased claudin-1 protein expression in hepatic metastatic
lesions of colorectal cancer. Anticancer Res. 32:2309–2314.
2012.PubMed/NCBI
|
|
17.
|
Ersoz S, Mungan S, Cobanoglu U, Turgutalp
H and Ozoran Y: Prognostic importance of Claudin-1 and Claudin-4
expression in colon carcinomas. Pathol Res Pract. 207:285–289.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Morohashi S, Kusumi T, Sato F, et al:
Decreased expression of claudin-1 correlates with recurrence status
in breast cancer. Int J Mol Med. 20:139–143. 2007.PubMed/NCBI
|
|
19.
|
Zhang Z, Wang A, Sun B, Zhan Z, Chen K and
Wang C: Expression of CLDN1 and CLDN10 in lung adenocarcinoma in
situ and invasive lepidic predominant adenocarcinoma. J
Cardiothorac Surg. 8:952013. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Matsuda Y, Semba S, Ueda J, et al: Gastric
and intestinal claudin expression at the invasive front of gastric
carcinoma. Cancer Sci. 98:1014–1019. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Suh Y, Yoon CH, Kim RK, et al: Claudin-1
induces epithelialmesenchymal transition through activation of the
c-Abl-ERK signaling pathway in human liver cells. Oncogene.
32:4873–4882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Singh AB, Sharma A and Dhawan P: Claudin-1
expression confers resistance to anoikis in colon cancer cells in a
Src-dependent manner. Carcinogenesis. 33:2538–2547. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Singh AB, Sharma A, Smith JJ, et al:
Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin
expression in colon cancer cells. Gastroenterology. 141:2140–2153.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Shiozaki A, Bai XH, Shen-Tu G, et al:
Claudin 1 mediates TNFalpha-induced gene expression and cell
migration in human lung carcinoma cells. PLoS One. 7:e380492012.
View Article : Google Scholar
|
|
25.
|
Di Cello F, Cope L, Li H, et al:
Methylation of the claudin 1 promoter is associated with loss of
expression in estrogen receptor positive breast cancer. PLoS One.
8:e686302013.PubMed/NCBI
|
|
26.
|
Blanchard AA, Skliris GP, Watson PH, et
al: Claudins 1, 3, and 4 protein expression in ER negative breast
cancer correlates with markers of the basal phenotype. Virchows
Arch. 454:647–656. 2009. View Article : Google Scholar
|
|
27.
|
Moldvay J, Jackel M, Paska C, Soltesz I,
Schaff Z and Kiss A: Distinct claudin expression profile in
histologic subtypes of lung cancer. Lung Cancer. 57:159–167. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Miwa N, Furuse M, Tsukita S, Niikawa N,
Nakamura Y and Furukawa Y: Involvement of claudin-1 in the
beta-catenin/Tcf signaling pathway and its frequent upregulation in
human colorectal cancers. Oncol Res. 12:469–476. 2001. View Article : Google Scholar
|
|
29.
|
Bhat AA, Sharma A, Pope J, et al: Caudal
homeobox protein Cdx-2 cooperates with Wnt pathway to regulate
claudin-1 expression in colon cancer cells. PLoS One. 7:e371742012.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Shiou SR, Singh AB, Moorthy K, et al:
Smad4 regulates claudin-1 expression in a transforming growth
factor-beta-independent manner in colon cancer cells. Cancer Res.
67:1571–1579. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Sharma A, Bhat AA, Krishnan M, Singh AB
and Dhawan P: Trichostatin-A modulates claudin-1 mRNA stability
through the modulation of Hu antigen R and tristetraprolin in colon
cancer cells. Carcinogenesis. 34:2610–2621. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Krishnan M, Singh AB, Smith JJ, et al:
HDAC inhibitors regulate claudin-1 expression in colon cancer cells
through modulation of mRNA stability. Oncogene. 29:305–312. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Sinicrope FA, Ruan SB, Cleary KR, Stephens
LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during
colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
|
|
34.
|
Mrsny RJ, Brown GT, Gerner-Smidt K, et al:
A key claudin extra-cellular loop domain is critical for epithelial
barrier integrity. Am J Pathol. 172:905–915. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Stebbing J, Filipovic A and Giamas G:
Claudin-1 as a promoter of EMT in hepatocellular carcinoma.
Oncogene. 32:4871–4872. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Yoon CH, Kim MJ, Park MJ, et al: Claudin-1
acts through c-Abl-protein kinase Cdelta (PKCdelta) signaling and
has a causal role in the acquisition of invasive capacity in human
liver cells. J Biol Chem. 285:226–233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Zavala-Zendejas VE, Torres-Martinez AC,
Salas-Morales B, Fortoul TI, Montano LF and Rendon-Huerta EP:
Claudin-6, 7, or 9 overexpression in the human gastric
adenocarcinoma cell line AGS increases its invasiveness, migration,
and proliferation rate. Cancer Invest. 29:1–11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Soini Y, Tommola S, Helin H and
Martikainen P: Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of
claudin expression associates with the diffuse subtype. Virchows
Arch. 448:52–58. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Resnick MB, Gavilanez M, Newton E, et al:
Claudin expression in gastric adenocarcinomas: a tissue microarray
study with prognostic correlation. Hum Pathol. 36:886–892. 2005.
View Article : Google Scholar
|
|
40.
|
Wu YL, Zhang S, Wang GR and Chen YP:
Expression transformation of claudin-1 in the process of gastric
adenocarcinoma invasion. World J Gastroenterol. 14:4943–4948. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Demir R, Dimmler A, Naschberger E, et al:
Malignant progression of invasive tumour cells seen in hypoxia
present an accumulation of beta-catenin in the nucleus at the
tumour front. Exp Mol Pathol. 87:109–116. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Li YP, Wu CC, Chen WT, Huang YC and Chai
CY: The expression and significance of WWOX and beta-catenin in
hepatocellular carcinoma. APMIS. 121:120–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Ooi CH, Ivanova T, Wu J, et al: Oncogenic
pathway combinations predict clinical prognosis in gastric cancer.
PLoS Genet. 5:e10006762009. View Article : Google Scholar : PubMed/NCBI
|
